|
|
|
|
Thursday, August 8, 2019
TherapeuticsMD (TXMD)
Promising Quarter Signaling to a Positive 2H 2019
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products.
Ahu Demir, Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Exceeded our expectations. TherapeuticsMD reported the second quarter revenues of $6.1million (mm) beating our estimate ($4.7mm). The company also slightly raised full year 2019 revenue guidance to a range of $29.5-34.2mm from $27.1 to 33.1mm. This increase was derived from prenatal vitamin business, rather than FDA approved product revenues.
- Increasing payers coverage is fundamental. The company is on track securing last few top commercial (covering 71% commercial lives) and Part D payers. The contract amendments and decisions are expected…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.